Chemotherapy and Radiotherapy for Advanced Ovarian Cancer
Author Information
Author(s): J.A. Green, H.M. Warenius, R.D. Errington, S. Myint, G. Spearing, A.J. Slater
Primary Institution: Clatterbridge Hospital and Arrowe Park Hospital
Hypothesis
Can sequential cisplatin and cyclophosphamide chemotherapy followed by radiotherapy improve outcomes in advanced ovarian cancer?
Conclusion
The combination of chemotherapy and radiotherapy resulted in a 75% survival rate at 30 months for patients in complete remission.
Supporting Evidence
- 85% of patients received more than 75% of the calculated doses.
- 72% of evaluable patients achieved a complete response.
- Actuarial survival of the whole group is 60% at a median follow-up of 2 years.
- 75% survival rate at 30 months for patients receiving both treatments.
Takeaway
Doctors treated 46 women with advanced ovarian cancer using two types of medicine and found that most of them got better.
Methodology
Patients received five cycles of cisplatin and cyclophosphamide followed by radiotherapy to the abdomen and pelvis.
Limitations
The study had a small sample size and excluded patients over 70 years and those with other serious health issues.
Participant Demographics
Mean age was 56 years, with a range from 34 to 70 years.
Want to read the original?
Access the complete publication on the publisher's website